Poteligeo (Mogamulizumab-kpkc)
- Medicine Name: Poteligeo
- Generic Name: Mogamulizumab-kpkc
- Dosage Form & Strength: Injection: 20 mg/5 mL (4 mg/mL) solution in a single-dose vial
- Manufactured By: Kyowa Kirin, Inc.
Medical Uses
Poteligeo is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody used for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome (two rare types of non-Hodgkin lymphoma) after at least one prior systemic therapy.
Recommended Dosage: The recommended dose of Poteligeo injection is 1 mg/kg given as an intravenous infusion over at least 60 minutes.
Administer this medication on days 1’st, 8’th, 15’th, & 22’nd of the initial 28-day cycle, then on days 1’st & 15’th of each subsequent 28-day cycle until the disease is progressive or unacceptable toxicity occurs. Administer the injection within 2 days of the scheduled dose.
In case a dose is missed, administer the very next dose as quickly as possible and resume the dosing schedule. Do not administer this medicine subcutaneously or by rapid intravenous administration.
Administer premedication with acetaminophen and diphenhydramine for the first infusion of Poteligeo.
Warning & Precautions
- Fatal and life-threatening skin adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have occurred in recipients of Poteligeo injection. Rash is one of the most common side effects associated with this medicine.
- Assess patients for rash throughout the therapy course. Dermatologic toxicity needs to be managed. Consider skin biopsy to help distinguish medicine eruption from disease progression.
- Discontinue mogamulizumab permanently for SJS or TEN or for any hazardous (Grade-4) reaction. For possible SJS/TEN, interrupt treatment and do not reinitiate unless SJS/TEN is ruled out and the cutaneous reaction has resolved to Grade-1 or less.
- Fatal and hazardous infusion reactions have been reported in those treated with mogamulizumab. Most reactions (around 90%) emerge during or shortly after the 1’st infusion. Infusion reactions can also emerge with subsequent infusions. The most commonly reported signs include nausea, chills, fever, rigors, headache, tachycardia, and vomiting.
- Consider premedication (such as acetaminophen and diphenhydramine) for the first infusion of Poteligeo 20 mg/5 mL (4 mg/mL) in all patients. Assess patients precisely for signs/symptoms of infusion reactions and interrupt the infusion for any grade reaction and treat quickly.
- Fatal and hazardous infections have occurred in those treated with mogamulizumab, including pneumonia, sepsis, and skin infection. In Trial 1, 18% of patients randomized to mogamulizumab had Grade-3 or higher infection or an infection-related serious side effect. Assess patients for signs/symptoms of infection and treat quickly.
- Fatal and hazardous immune-mediated complications may occur in recipients of mogamulizumab. Interrupt or permanently interrupt this medicine as apt for suspected immune-mediated side effects. Consider the benefit/risk of mogamulizumab in those with a history of autoimmune disease.
- Increased risks of transplant complications may occur in those who receive allogeneic HSCT after Mogamulizumab 20 mg/5 mL (4 mg/mL) including severe (Grade 3/4) acute graft-versus-host disease (GVHD), steroid-refractory GVHD, and transplant-related death. Follow patients precisely for early outcomes of transplant-related complications.
- Mogamulizumab is not recommended during breastfeeding or pregnancy or in women of childbearing age not using contraception. For women of reproductive age, verify pregnancy status before initiating Mogamulizumab. Females of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose of Mogamulizumab.
Documentation & Availability
What documents are required to import POTELIGEO to India?
POTELIGEO (Mogamulizumab-kpkc) Injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is POTELIGEO available in India?
POTELIGEO (Mogamulizumab-kpkc Injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
S S Healthcare (S S Healthcare) helps import cancer medicines on the named patient supply (NPS). S S Healthcare is facilitator providing input
- On availability of Poteligeo injection in India (Pune, Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, and Bangalore, etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
POTELIGEO can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
S S Healthcare (S S Healthcare) can facilitate the supply of POTELIGEO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-7575883015 | Number: +91-7575883015 or write us at sshealthcare1012@gmail.com for Poteligeo price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
S S Healthcare is able to source the POTELIGEO (Cancer Treatment Medicines) from across the globe, and has the ability to supply. S S Healthcare offers its customers worldwide access to the best available treatment.
S S Healthcare is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Poteligeo®?
Mogamulizumab-kpkc is Generic Name for the trade name drug Poteligeo®.
What is the Manufacturer Name of Poteligeo®?
Poteligeo® is manufactured by Kyowa Kirin, Inc.
Is Poteligeo® approved by the FDA?
Yes, Poteligeo® is approved by the FDA. Date of first/initial approval: August 8, 2018.
What is the dosage and form of Poteligeo® supplied?
Poteligeo® is supplied as Injection: 20 mg/5 mL (4 mg/mL) as a clear to slightly opalescent colorless solution in a single dose vial for intravenous administration.
What are the most common side effects with Poteligeo®?
The most common side effects with Poteligeo® include: fatigue, rash, diarrhea, musculoskeletal pain, upper respiratory tract infection, and infusion related reactions.
How much does Poteligeo® cost in India?
Poteligeo (mogamulizumab) cost in India is less and can vary. In order to procure this MF/SS medication authentically, you can call or WhatsApp +91-7575883015 or send mail to sshealthcare1012@gmail.com.
What are the storage conditions of Poteligeo®?
Poteligeo® injection is a sterile, preservative-free, clear to slightly opalescent colorless solution that comes in a carton containing one 20 mg/5 mL (4 mg/mL), single-dose glass vial.
Store vials of Poteligeo under refrigeration at 2°C to 8°C (36°F to 46°F) in the original package to protect from light until time of use. Neither freeze nor shake.
Is it safe to buy Poteligeo® online from India?
Yes, You can buy Poteligeo in India online at the best price from S S Healthcare if Poteligeo® has not been approved or is not available in your country.
What are the Highlights of prescribing information for Poteligeo®?
Click Here to download full Poteligeo prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
